ENHANCE YOUR CARDIAC TESTING PANEL


The heart of the matter is, Cardiovascular disease (CVD) is a leading cause of death worldwide and continues to increase in prevalence. A growing body of research indicates that further markers for the diagnosis and prognosis of cardiac risk needs to be considered, as the conventional markers such as LDL-C, HDL-C, total cholesterol and triglycerides, only detect a mere 20% of all atherosclerotic cardiovascular disease patients.


Early risk assessment is therefore vital to ensure effective treatment plan implementation and to prevent a secondary coronary event. Randox understand the necessity of superior assays in the diagnosis and prognosis of CVD. Explore the Randox range of high performance and unique tests that can enhance your cardiac testing capabilities.


OPEN CHANNEL CARDIAC REAGENTS


Apolipoprotein C-ll Apolipoprotein C-lll Apolipoprotein E Homocysteine Lipoprotein(a)


Small Dense LDL Cholesterol


KEY BENEFITS » Liquid ready-to-use reagents » Direct, automated assays » Excellent correlation to gold standard methods » Instrument specific applications available


www.randox.com | reagents@randox.com CONTACT US TODAY


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54